TWI547492B - ７－｛（３ｓ，４ｓ）－３－［（環丙胺基）甲基］－４－氟吡咯啶－１－基｝－６－氟－１－（２－氟乙基）－８－甲氧基－４－側氧－１，４－二氫喹啉－３－甲酸之晶體 - Google Patents
７－｛（３ｓ，４ｓ）－３－［（環丙胺基）甲基］－４－氟吡咯啶－１－基｝－６－氟－１－（２－氟乙基）－８－甲氧基－４－側氧－１，４－二氫喹啉－３－甲酸之晶體 Download PDFInfo
- Publication number
- TWI547492B TWI547492B TW101141841A TW101141841A TWI547492B TW I547492 B TWI547492 B TW I547492B TW 101141841 A TW101141841 A TW 101141841A TW 101141841 A TW101141841 A TW 101141841A TW I547492 B TWI547492 B TW I547492B
- Authority
- TW
- Taiwan
- Prior art keywords
- crystal
- fluoro
- oxo
- fluoroethyl
- dihydroquinoline
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title claims description 260
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 title claims description 38
- 125000006317 cyclopropyl amino group Chemical group 0.000 title claims description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 89
- KFZMGEQAYNKOFK-UHFFFAOYSA-N isopropyl alcohol Natural products CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 85
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 67
- 239000000243 solution Substances 0.000 claims description 67
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 62
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 48
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 44
- 238000004455 differential thermal analysis Methods 0.000 claims description 36
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 36
- 230000000694 effects Effects 0.000 claims description 28
- 239000003242 anti bacterial agent Substances 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 21
- 238000004458 analytical method Methods 0.000 claims description 18
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 13
- 230000004580 weight loss Effects 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- 238000010998 test method Methods 0.000 claims description 7
- 238000002411 thermogravimetry Methods 0.000 claims description 7
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 claims description 5
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 4
- ZFIOCUITTUUVPV-MEDUHNTESA-N 7-[(3s,4s)-3-[(cyclopropylamino)methyl]-4-fluoropyrrolidin-1-yl]-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound C([C@@H]1[C@H](F)CN(C1)C1=C(C2=C(C(C(C(O)=O)=CN2CCF)=O)C=C1F)OC)NC1CC1 ZFIOCUITTUUVPV-MEDUHNTESA-N 0.000 claims description 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 69
- 150000001875 compounds Chemical class 0.000 description 66
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- 238000002425 crystallisation Methods 0.000 description 25
- 230000008025 crystallization Effects 0.000 description 25
- 239000002904 solvent Substances 0.000 description 22
- 239000011541 reaction mixture Substances 0.000 description 21
- 239000000047 product Substances 0.000 description 17
- 239000010410 layer Substances 0.000 description 15
- 238000003860 storage Methods 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 13
- 238000001914 filtration Methods 0.000 description 12
- 239000011877 solvent mixture Substances 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 238000010438 heat treatment Methods 0.000 description 9
- 238000000354 decomposition reaction Methods 0.000 description 8
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 7
- 239000004327 boric acid Substances 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 238000002076 thermal analysis method Methods 0.000 description 7
- 238000000921 elemental analysis Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 229910052796 boron Inorganic materials 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- -1 8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid mesylate Chemical compound 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 125000002091 cationic group Chemical group 0.000 description 4
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 229940127557 pharmaceutical product Drugs 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- YQHZQIJEMFMUGH-DFIJPDEKSA-N 7-[(3s,4s)-3-[(cyclopropylamino)methyl]-4-fluoropyrrolidin-1-yl]-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxoquinoline-3-carboxylic acid;hydrochloride Chemical compound Cl.C([C@@H]1[C@H](F)CN(C1)C1=C(C2=C(C(C(C(O)=O)=CN2CCF)=O)C=C1F)OC)NC1CC1 YQHZQIJEMFMUGH-DFIJPDEKSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- DIIIISSCIXVANO-UHFFFAOYSA-N 1,2-Dimethylhydrazine Chemical compound CNNC DIIIISSCIXVANO-UHFFFAOYSA-N 0.000 description 2
- PKLMRMLZKXZQHS-UHFFFAOYSA-N 1-(2-fluoroethyl)-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FCCN1C=C(C(C2=CC=CC(=C12)OC)=O)C(=O)O PKLMRMLZKXZQHS-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- SCUNBUHKGUUZQS-UHFFFAOYSA-N 2-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FC=1N(C2=C(C=CC=C2C(C=1C(=O)O)=O)OC)CCF SCUNBUHKGUUZQS-UHFFFAOYSA-N 0.000 description 2
- CDGYPATWKVOBIY-UHFFFAOYSA-N 8-methoxy-4-oxo-1h-quinoline-3-carboxylic acid Chemical compound N1C=C(C(O)=O)C(=O)C2=C1C(OC)=CC=C2 CDGYPATWKVOBIY-UHFFFAOYSA-N 0.000 description 2
- 102100025142 Beta-microseminoprotein Human genes 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 101100185029 Homo sapiens MSMB gene Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- IANXAXNUNBAWBA-UHFFFAOYSA-N 2,2,3-trimethylundecane Chemical compound CCCCCCCCC(C)C(C)(C)C IANXAXNUNBAWBA-UHFFFAOYSA-N 0.000 description 1
- LJOOAEVVWPYVPO-WJMOHVQJSA-N 7-[(3s,4s)-3-[(cyclopropylamino)methyl]-4-fluoropyrrolidin-1-yl]-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxoquinoline-3-carboxylic acid;hydrate;hydrochloride Chemical compound O.Cl.C([C@@H]1[C@H](F)CN(C1)C1=C(C2=C(C(C(C(O)=O)=CN2CCF)=O)C=C1F)OC)NC1CC1 LJOOAEVVWPYVPO-WJMOHVQJSA-N 0.000 description 1
- VWUUWHZWYRHUAB-UHFFFAOYSA-N 8-methoxy-4-oxo-1H-quinoline-3-carboxylic acid hydrate hydrochloride Chemical compound COC1=CC=CC2=C1NC=C(C2=O)C(=O)O.O.Cl VWUUWHZWYRHUAB-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- ZCLMJVVMIFVARP-XHDDUAGMSA-N COC1=C2C(=CC(=C1N3C[C@@H]([C@@H](C3)F)CNC4CC4)F)C(=O)C(C(=O)N2CCF)C(=O)O Chemical compound COC1=C2C(=CC(=C1N3C[C@@H]([C@@H](C3)F)CNC4CC4)F)C(=O)C(C(=O)N2CCF)C(=O)O ZCLMJVVMIFVARP-XHDDUAGMSA-N 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- NIOXJPOGNYEUNC-UHFFFAOYSA-N O=C1C(C(O)=O)C(=O)NC2=C1C=CC=C2OC Chemical compound O=C1C(C(O)=O)C(=O)NC2=C1C=CC=C2OC NIOXJPOGNYEUNC-UHFFFAOYSA-N 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- GDTFEFIMHDUGFS-UHFFFAOYSA-N ethyl 6,7-difluoro-1-(2-fluoroethyl)-8-methoxy-4-oxoquinoline-3-carboxylate Chemical compound FC1=C(F)C=C2C(=O)C(C(=O)OCC)=CN(CCF)C2=C1OC GDTFEFIMHDUGFS-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical class [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011246209 | 2011-11-10 | ||
| JP2012071739 | 2012-03-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201332991A TW201332991A (zh) | 2013-08-16 |
| TWI547492B true TWI547492B (zh) | 2016-09-01 |
Family
ID=48289529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW101141841A TWI547492B (zh) | 2011-11-10 | 2012-11-09 | ７－｛（３ｓ，４ｓ）－３－［（環丙胺基）甲基］－４－氟吡咯啶－１－基｝－６－氟－１－（２－氟乙基）－８－甲氧基－４－側氧－１，４－二氫喹啉－３－甲酸之晶體 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US9090587B2 (enExample) |
| EP (2) | EP3112359B1 (enExample) |
| JP (4) | JP5871948B2 (enExample) |
| KR (2) | KR102162208B1 (enExample) |
| CN (2) | CN104945375B (enExample) |
| AU (1) | AU2016273899B2 (enExample) |
| BR (1) | BR112014010765B1 (enExample) |
| CA (1) | CA2855022C (enExample) |
| ES (2) | ES2621664T3 (enExample) |
| IN (1) | IN2014DN03277A (enExample) |
| MX (1) | MX375073B (enExample) |
| NZ (1) | NZ623808A (enExample) |
| RU (2) | RU2615509C2 (enExample) |
| SA (1) | SA112330992B1 (enExample) |
| SG (2) | SG10201608167UA (enExample) |
| TW (1) | TWI547492B (enExample) |
| WO (1) | WO2013069297A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12594418B2 (en) | 2011-03-10 | 2026-04-07 | Electrocore, Inc. | Devices and methods for nerve stimulation |
| SA112330992B1 (ar) * | 2011-11-10 | 2015-09-13 | كيورين فارماسوتيكال كو.، ليمتد | صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي |
| CN105338982B (zh) | 2013-04-25 | 2017-10-10 | 杏林制药株式会社 | 固体药用组合物 |
| JP6349306B2 (ja) * | 2013-04-25 | 2018-06-27 | 杏林製薬株式会社 | 錠剤 |
| US9687453B2 (en) | 2013-04-25 | 2017-06-27 | Kyorin Pharmaceutical Co., Ltd. | Solid pharmaceutical composition |
| GB201402071D0 (en) * | 2014-02-07 | 2014-03-26 | Galapagos Nv | Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| JP6018334B2 (ja) * | 2014-10-23 | 2016-11-02 | 杏林製薬株式会社 | 固形医薬組成物 |
| EP3210608A4 (en) * | 2014-10-23 | 2018-06-20 | Kyorin Pharmaceutical Co., Ltd. | Solid pharmaceutical composition |
| MX380385B (es) | 2015-03-13 | 2025-03-12 | Kyorin Seiyaku Kk | Agente para el tratamiento de infeccion respiratoria. |
| WO2016195020A1 (ja) * | 2015-06-02 | 2016-12-08 | 杏林製薬株式会社 | 水性液剤 |
| JP6031217B1 (ja) | 2015-06-02 | 2016-11-24 | 杏林製薬株式会社 | 水性液剤 |
| WO2016195014A1 (ja) * | 2015-06-02 | 2016-12-08 | 杏林製薬株式会社 | 水性液剤 |
| MY200429A (en) | 2017-06-16 | 2023-12-26 | Kyorin Seiyaku Kk | Therapeutic agent for aspiration pneumonia, lung suppuration, or lung abscess |
| CA3067188A1 (en) | 2017-06-16 | 2018-12-20 | Kyorin Pharmaceutical Co., Ltd. | Therapeutic agent for aspiration pneumonia, lung suppuration, or lung abscess |
| GB201808575D0 (en) | 2018-05-24 | 2018-07-11 | Galapagos Nv | Methods for the treatment of psoriatic arthrits |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1849316A (zh) * | 2003-09-10 | 2006-10-18 | 杏林制药株式会社 | 7－(4－取代－3－环丙基氨基甲基－1－吡咯烷基)喹诺酮羧酸衍生物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA944369B (en) * | 1993-08-27 | 1995-02-13 | Hokuriku Seuyaku Co Ltd | 5-amino-8-methyl-7-pyrrolidinylquinoline-3-carboxylic acid derivative |
| CN1158846A (zh) * | 1995-05-09 | 1997-09-10 | 昆山市康壮达兽药厂 | 盐酸氟哌酸的合成工艺 |
| WO2003014732A1 (en) | 2001-08-10 | 2003-02-20 | Symyx Technologies, Inc. | Apparatuses and methods for creating and testing pre-formulations and systems for same |
| AU2002236267A1 (en) * | 2002-03-08 | 2003-09-22 | Daiichi Pharmaceutical Co., Ltd. | Quinolonecarboxylic acid derivative |
| CN101003540A (zh) * | 2006-01-18 | 2007-07-25 | 广州白云山制药股份有限公司广州白云山制药总厂 | 一种抗感染化合物和用途 |
| SA112330992B1 (ar) * | 2011-11-10 | 2015-09-13 | كيورين فارماسوتيكال كو.، ليمتد | صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي |
-
2012
- 2012-11-07 SA SA112330992A patent/SA112330992B1/ar unknown
- 2012-11-09 ES ES12846895.6T patent/ES2621664T3/es active Active
- 2012-11-09 KR KR1020197015481A patent/KR102162208B1/ko active Active
- 2012-11-09 CN CN201510329284.3A patent/CN104945375B/zh active Active
- 2012-11-09 RU RU2014123567A patent/RU2615509C2/ru active
- 2012-11-09 SG SG10201608167UA patent/SG10201608167UA/en unknown
- 2012-11-09 EP EP16177827.9A patent/EP3112359B1/en not_active Not-in-force
- 2012-11-09 NZ NZ623808A patent/NZ623808A/en not_active IP Right Cessation
- 2012-11-09 JP JP2013542858A patent/JP5871948B2/ja active Active
- 2012-11-09 KR KR1020147012681A patent/KR20140098074A/ko not_active Ceased
- 2012-11-09 RU RU2017109814A patent/RU2017109814A/ru unknown
- 2012-11-09 US US14/352,141 patent/US9090587B2/en not_active Expired - Fee Related
- 2012-11-09 BR BR112014010765-3A patent/BR112014010765B1/pt not_active IP Right Cessation
- 2012-11-09 IN IN3277DEN2014 patent/IN2014DN03277A/en unknown
- 2012-11-09 CN CN201280055120.0A patent/CN103930414B/zh active Active
- 2012-11-09 EP EP12846895.6A patent/EP2778159B1/en not_active Not-in-force
- 2012-11-09 CA CA2855022A patent/CA2855022C/en not_active Expired - Fee Related
- 2012-11-09 SG SG11201401817TA patent/SG11201401817TA/en unknown
- 2012-11-09 ES ES16177827T patent/ES2747303T3/es active Active
- 2012-11-09 WO PCT/JP2012/007195 patent/WO2013069297A1/ja not_active Ceased
- 2012-11-09 TW TW101141841A patent/TWI547492B/zh active
- 2012-11-09 MX MX2017006000A patent/MX375073B/es unknown
-
2015
- 2015-06-17 US US14/741,713 patent/US9328089B2/en not_active Ceased
- 2015-08-25 JP JP2015165879A patent/JP6514069B2/ja active Active
-
2016
- 2016-12-14 AU AU2016273899A patent/AU2016273899B2/en not_active Ceased
-
2017
- 2017-05-08 JP JP2017092125A patent/JP6349435B2/ja active Active
-
2018
- 2018-05-02 US US15/969,342 patent/USRE47785E1/en not_active Expired - Fee Related
- 2018-07-13 JP JP2018132781A patent/JP6818719B2/ja active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1849316A (zh) * | 2003-09-10 | 2006-10-18 | 杏林制药株式会社 | 7－(4－取代－3－环丙基氨基甲基－1－吡咯烷基)喹诺酮羧酸衍生物 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6818719B2 (ja) | ７−｛（３ｓ、４ｓ）−３−［（シクロプロピルアミノ）メチル］−４−フルオロピロリジン−１−イル｝−６−フルオロ−１−（２−フルオロエチル）−８−メトキシ−４−オキソ−１、４−ジヒドロキノリン−３−カルボン酸の結晶 | |
| JP7061115B2 (ja) | 嚢胞性線維症膜コンダクタンス制御因子の調節因子、医薬組成物、処置の方法、及び当該調節因子を作製するためのプロセス | |
| CN114728899A (zh) | 新型三苯基化合物盐 | |
| EP3205653B1 (en) | Crystal form of bisulfate of jak inhibitor and preparation method therefor | |
| AU2016384921A1 (en) | Crystalline form of BTK kinase inhibitor and preparation method thereof | |
| WO2017008773A1 (en) | Crystalline forms of obeticholic acid | |
| JP2025524904A (ja) | ダプロデュスタットおよびその共結晶を調整するための方法 | |
| AU2012337206B8 (en) | 7-{(3S,4S)-3-[(cyclopropylamino)methyl]-4-fluoropyrrolidine-1-yl}-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid crystal | |
| MX2014005007A (es) | Cristal del acido 7-{(3s,4s)-3-[(ciclopropilamino)metil]-4-fluorop irrolidin-1-il}-6-fluoro-1-(fluoroetil)-8-metoxi-4-oxo-1,4-dihidr oquinolin-3-carboxilico. | |
| HK1256344A1 (en) | Process for producing an aminopyrrolidine derivative | |
| WO2018054359A1 (zh) | 一种喹唑啉衍生物的盐、其制备方法及应用 | |
| MXPA06008491A (en) | Crystal forms of e-2-methoxy -n-(3-{4-[3-methyl -4-(6-methyl- pyridin-3 -yloxy)-phenylamino]-quinazolin-6-yl} -allyl)- acetamide |